Last reviewed · How we verify
NCT04657848
Preliminary Efficacy Analysis of Cheng's Giraffe Reconstruction After Proximal Gastrectomy
NA trial testing proximal gastrectomy combined with Cheng's Giraffe reconstruction in Gastric Cancer in 100 participants. Status unknown.
1 June 2021
Quick facts
| Lead sponsor | Zhejiang Cancer Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 1 June 2020 |
| Primary completion | 1 June 2021 |
| Estimated completion | 1 June 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- proximal gastrectomy combined with Cheng's Giraffe reconstruction
Conditions studied
- Gastric Cancer — all drugs for Gastric Cancer →
- Reflux Esophagitis — all drugs for Reflux Esophagitis →
Sponsor
Zhejiang Cancer Hospital
Who can join
Adults 18 to 70, any sex, with Gastric Cancer or Reflux Esophagitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In the past years, the adenocarcinoma of the esophagogastric junction (AEG) has been increasing obviously in China. It may be caused by the reason of increased body weight, alcohol consumption, gastroesophageal reflux disease and premalignant. In western countries, the 5-year rate of advanced AEG was less than 30%, it was the same in China. There was significant difference in epidemiology, pathogenic mechanism, biological characteristics and prognosis between AEG and antrum tumors, so AEG was regarded as a kind of independent disease. Up till now, the scope of lymph node dissected, the selection of operation approach, the resection range and the digestive tract reconstruction for the treatment of AEG were in dispute, especially in the reconstruction of digestive tract after operation. The purpose of this study is to investigate the efficacy and safety of the proximal gastrectomy combined with Giraffe anastomosis for early adenocarcinoma of esophagogastric junction.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Efficacy analysis of Cheng's GIRAFFE reconstruction after proximal gastrectomy for adenocarcinoma of esophagogastric junction.
Xu Z, Hu C, Zhang Y, Huang L, et al · · 2022 · cited 7× · PMID 35873890 · DOI 10.21147/j.issn.1000-9604.2022.03.08 -
Current clinical trials on gastric cancer surgery in China.
Zhang S, Hu RH, Cui XM, Song C, et al · · 2024 · PMID 39554743 · DOI 10.4251/wjgo.v16.i11.4369
Verify or expand the search:
- PubMed search for NCT04657848
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastric Cancer
Currently open trials in the same condition.
- NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
- NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
- NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
Other Zhejiang Cancer Hospital trials
Trials by the same sponsor.
- NCT07343479 — Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases · Phase 2 · not yet recruiting
- NCT07441720 — Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT) · Phase 2 · recruiting
- NCT07416890 — Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Ref · Phase 2 · recruiting
- NCT07326150 — Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Canc · active not recruiting
- NCT07330544 — A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Rec · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04657848 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhejiang Cancer Hospital
- Last refreshed: 8 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04657848.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing